Startups  March 31, 2026

Ambrosia Bio raises $100M for oral GLP-1 trial

Ambrosia Biosciences has closed an $100 million Series B round to fund clinical trials of its oral small molecule GLP-1 weight loss drug candidate. 

Lucas is an award-winning journalist who worked at news agencies from Maryland to Wyoming to South Carolina before putting roots down in Colorado.

Related Posts

Sign up for BizWest Daily Alerts
Closing in 8 seconds...